궁금한 내용을 주주들과 공유해 보세요. 바로가기>>
PharmAbcine Appoints Legendary Pathologist Dr. David Cheresh to Scientific Advisory Board.
DAEJEON, Republic of Korea, March 00, 2019 / PharmAbcine Inc. (KOSDAQ: 208340), a biopharmaceutical company focused on the development of antibody therapeutics for life, today announced the appointment of David Cheresh, Ph.D, to its Scientific Advisory Board. Dr. David Cheresh, well known cancer and vascular biologist . He is currently working on signaling aspects of cell invasion by vascular cells and tumor cells, with a focus on preventing tumor metastasis. He has published broadly in the areas of angiogenesis and oncology. His work has led to the development of significant cancer drugs, including Unituxin, approved by the FDA in 2015 as a first line therapy for high-risk neuroblastoma, and Vitaxin, a humanized monoclonal antibody in Phase II trials that targets vascular integrin ανβ3, inhibiting angiogenesis in several cancer types.
"On behalf of the management team and the Board, I am delighted to welcome Dr. David Cheresh to PharmAbcine. Dr. Cheresh’s renowned scientific expertise and experience in both angiogenesis and oncology will be superb asset as we continue to advance the development of TTAC-0001, PMC-001, PMC-002R, PMC-201, PMC-402 and PMC-401s. Additionally, we look forward to Dr. Cheresh’s guidance in evaluating future product portfolio expansion opportunities, including TTAC-0001’s use in Keytruda combination therapies for refractory cancers," said Dr. Jin-San Yoo, CEO and Chairman of PharmAbcine's Board of Directors.
Currently, Dr. Cheresh is a distinguished professor and vice chair of research in the Department of Pathology in the School of Medicine at the University of California, San Diego (UCSD). He is also Director for Translational Research at the Moores UCSD Cancer Center. Dr. Cheresh was a professor in the Departments of Immunology and Vascular Biology at The Scripps Research Institute, focusing on the role of adhesion receptors and growth factors in the angiogenesis of tumors. Dr. Cheresh earned his Ph.D. in Immunology from the University of Miami, FL and trained as a postdoctoral scientist at the Scripps Research Institute where he remained on the faculty before joining UCSD in 2005. He is the recipient of various awards including the 15th Hans Linder Memorial Lecture from the Weizmann Institute of Science in Rehovot, Israel, the XXIII Annual Myron Karon Memorial Lectureship from the University of Southern California, the Robert Flynn Professorship Award from Tufts University School of Medicine, the Judah Folkman lectureship, the Paget-Ewing award from the Metastasis Research Society/AACR and was a recipient of The American Cancer Society Faculty Research Award and a Merit Award from the National Cancer Institute. Dr. Cheresh also is a recipient of an NIH MERIT award and recently received the Outstanding Investigator Award from the National Cancer Institute..
"I am thrilled to join PharmAbcine’s Scientific Advisory Board at such a critical juncture in the Company's development," said Dr. Cheresh. I look forward to working closely with PharmAbcine’s management team and the Board to continue cultivating the Company's future and development path, including the potential of combination therapies with already approved drugs which may provide new treatments for oncology patients with no viable alternatives."
About PharmAbcine, Inc.
PharmAbcine Inc. is a leading clinical stage biopharmaceutical company that develops fully human therapeutic antibody (mAb) and next generation multispecific antibody therapeutics based on in-house developed novel platform, DIG-Body, PIG-Body and TIG-Body using innovative discovery technology and excellent human resources for the treatment of human diseases, such as cancer and inflammatory diseases.
PharmAbcine’s fully human antibody libraries and innovative selection system are our priceless proprietary assets. PharmAbcine provides antibody generation services by using antibody library and selection systems. PharmAbcine also provides co-development opportunities with novel antibodies.
Under the collaboration with SAMSUNG MEDICAL CENTER, PharmAbcine has more than 300 patients derived cancer stem cell libraries and its animal model system for evaluating internal pipeline development.
Selected pipeline.
TTAC-0001(Tanibirumab): anti-KDR neutralizing fully human IgG with unique cross species cross reactivity has completed its Phase IIa recurrent GBM trial in Australia in August 2017. Promising molecule to combine with immune checkpoint blockade is open for out-licensing, co-development and combination clinical trials.
PMC-001(DIG-KT): next generation bispecific antibody neutralizing both VEGF-KDR and Angiopoietin-TIE2 pathways is superior to bevacizumab and Tanibirumab in preliminary studies. It also overcomes the Avastin® resistant brain tumor growth. Both PMC-002 and PMC-002R are different scaffolds neutralizing same targets like PMC-001.
PMC-201: next generation bispecific antibody neutralizing both VEGF-KDR and Notch-DLL4 pathways overcomes anti-cancer drug resistant tumor growth.
PMC-005BL: Anti-EGFRviii truly specific fully human IgG with internalization property is perfect for ADC, CAR-T and CAR-NK purpose and is open for co-development or out-licensing.
PMC-309a-z: anti-VISTA fully human antibodies collection as either agonistic or antagonistic. Antagonistic antibody performed synergy effects in combination with other immuno-oncology drug.
"3G-System" platform provides high performing production cell lines and we do have both
PMC-901: bevacizumab biosimilar cell line with 3g/L productivity.
PMC-902: aflibercept biosimilar cell line with > 3g/L productivity.
For additional information about PharmAbcine is available through its website, http://www.pharmabcine.com
본 내용은 참고정보로, 최종 투자 판단의 책임은
본 게시물을 열람하는 이용자에게 있습니다.